Dyne Therapeutics
Healthcare & Life Sci
Company overview
Dyne Therapeutics is a biotechnology company. It develops nucleic acid therapies for rare neuromuscular diseases. Its pipeline includes zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy, zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, and DYNE-302 for facioscapulohumeral muscular dystrophy. The company is based in Waltham, Massachusetts.
Dyne Therapeutics trades on the Nasdaq stock exchange. That matters: as a public company, it must share its finances and drug trial results with regulators, so people can follow its progress. Dyne Therapeutics is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Waltham, United States